Integragen (PA:ALINT) — Market Cap & Net Worth
Market Cap & Net Worth: Integragen (ALINT)
Integragen (PA:ALINT) has a market capitalization of $319.78K (€273.52K) as of October 9, 2026. Listed on the PA stock exchange, this France-based company holds position #31211 globally and #587 in its home market, demonstrating a -41.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Integragen's stock price €0.04 by its total outstanding shares 6606796 (6.61 Million).
Integragen Market Cap History: 2015 to 2026
Integragen's market capitalization history from 2015 to 2026. Data shows change from $34.68 Million to $319.78K (-36.79% CAGR). Check ALINT share price today for real-time trading data and today's change.
Integragen Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Integragen's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Integragen cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.50x
Integragen's market cap is 0.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $34.68 Million | $5.79 Million | -$1.53 Million | 5.99x | N/A |
| 2016 | $26.18 Million | $6.27 Million | -$1.65 Million | 4.17x | N/A |
| 2017 | $19.62 Million | $6.51 Million | -$862.17K | 3.01x | N/A |
| 2018 | $8.57 Million | $6.95 Million | -$1.14 Million | 1.23x | N/A |
| 2019 | $7.80 Million | $8.28 Million | -$285.00K | 0.94x | N/A |
| 2020 | $15.83 Million | $8.98 Million | -$375.02K | 1.76x | N/A |
| 2021 | $8.56 Million | $11.32 Million | $15.41K | 0.76x | 555.48x |
| 2022 | $9.35 Million | $13.17 Million | -$3.51K | 0.71x | N/A |
| 2023 | $6.91 Million | $12.54 Million | -$171.40K | 0.55x | N/A |
| 2024 | $4.36 Million | $8.70 Million | -$256.00K | 0.50x | N/A |
Competitor Companies of ALINT by Market Capitalization
Companies near Integragen in the global market cap rankings as of October 9, 2026. See ALINT equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Integragen by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $128.16 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.06 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.47 Billion USD ( AU$88.29 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.16 Billion | $505.64 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.06 Billion | $742.12 |
| #450 | CSL Ltd | AU:CSL | $62.47 Billion | AU$181.99 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $196.48 |
Integragen Historical Marketcap From 2015 to 2026
Between 2015 and today, Integragen's market cap moved from $34.68 Million to $ 319.78K, with a yearly change of -36.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €319.78K | -68.87% |
| 2025 | €1.03 Million | -76.46% |
| 2024 | €4.36 Million | -36.80% |
| 2023 | €6.91 Million | -26.12% |
| 2022 | €9.35 Million | +9.21% |
| 2021 | €8.56 Million | -45.95% |
| 2020 | €15.83 Million | +102.97% |
| 2019 | €7.80 Million | -9.01% |
| 2018 | €8.57 Million | -56.30% |
| 2017 | €19.62 Million | -25.07% |
| 2016 | €26.18 Million | -24.50% |
| 2015 | €34.68 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 8th, 2026 the market cap of Integragen was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $319.78K USD |
| MoneyControl | $319.78K USD |
| MarketWatch | $319.78K USD |
| marketcap.company | $319.78K USD |
| Reuters | $319.78K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more